A new approach to personalized treatments for liver cancer
AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS
This study is exploring new ways to treat liver cancer by using special models to learn more about the disease, with the goal of finding better and safer treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10892810 on NIH RePORTER |
What this research studies
This research focuses on developing innovative therapies for liver cancer, specifically hepatocellular carcinoma (HCC), which is a leading cause of cancer-related deaths. The team will utilize advanced techniques, including genetically-engineered mouse models and 3D tumor organoids, to better understand the unique genetic and epigenetic characteristics of liver tumors. By identifying specific drug targets and testing new compounds, the research aims to improve treatment outcomes for patients with HCC. The approach seeks to move beyond current therapies that often provide limited benefits and significant side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced hepatocellular carcinoma who may not have responded well to existing treatments.
Not a fit: Patients with early-stage liver cancer or those whose cancer is not hepatocellular carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for liver cancer patients, potentially improving survival rates and quality of life.
How similar studies have performed: Other research has shown promise in using personalized approaches and genetic profiling to improve cancer therapies, indicating potential success for this novel approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Guccione, Ernesto — Icahn School of Medicine at Mount Sinai
- Study coordinator: Guccione, Ernesto
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.